Safety Efficacy Evidence Indication&Attributes Prescribing-information Previous Next Over A Decade of Improving Patient Outcomes MICARDIS® (TELMISARTAN) REDUCES THE NEW DEVELOPMENT OF LEFT VENTRICULAR HYPERTROPHY 17/01/2022 | Author: Boehringer IngelheimONTARGET: MICARDIS® (TELMISARTAN) REDUCED THE PREVALENCE OF LEFT VENTRICULAR HYPERTROPHY SIMILAR TO RAMIPRIL Document ID: PC-SA-101596 | Expiry Date: 01/05/2026 MICARDIS® (TELMISARTAN) REDUCES THE NEW DEVELOPMENT OF LEFT VENTRICULAR HYPERTROPHY ONTARGET TRIAL: MICARDIS®80 (TELMISARTAN) REDUCTION IN COMPOSITE CV RISK MICARDIS® (TELMISARTAN) HAS PLACEBO-LIKE TOLERABILITY Related content Read more PDF MICARDIS® (TELMISARTAN) HAS PLACEBO-LIKE TOLERABILITY PC-SA-101593 (April 2026 ) Download Opens in new tab Read more PDF ONTARGET TRIAL: MICARDIS®80 (TELMISARTAN) REDUCTION IN COMPOSITE CV RISK PC-SA-101594 (May 2026 ) Download Opens in new tab Home Cardiovascular | Therapeutic Area Telmisartan MICARDIS® (TELMISARTAN) REDUCES THE NEW DEVELOPMENT OF LEFT VENTRICULAR HYPERTROPHY
Read more PDF MICARDIS® (TELMISARTAN) HAS PLACEBO-LIKE TOLERABILITY PC-SA-101593 (April 2026 ) Download Opens in new tab
Read more PDF ONTARGET TRIAL: MICARDIS®80 (TELMISARTAN) REDUCTION IN COMPOSITE CV RISK PC-SA-101594 (May 2026 ) Download Opens in new tab
